Phase 3
Completed N=735
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
Bacterial Infections · Skin Structures and Soft Tissue Infections
Source: ClinicalTrials.gov NCT02877927 ↗
Enrolled (actual)
735
Serious AEs
1.4%
Results posted
Nov 2018
Primary outcomePrimary: Number of Participants With Early Clinical Response — 315; 297; 26; 32 Participants
◆ Published Evidence
Established
94citations · ~13 / year
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
Summary
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.
Linked Publications (5)
-
Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
-
Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections.
-
Safety and efficacy of omadacycline for treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in patients with mild-to-moderate renal impairment.
-
Intravenous Versus Oral Omadacycline or Linezolid for Acute Bacterial Skin and Skin Infections: A post hoc Analysis of the OASIS Trials.
-
Omadacycline in Skin Infections and Pneumonia: A Review of the Evidence.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Early Clinical Response |
315; 297; 26; 32; 19; 31 | — |
| SECONDARY Number of Participants With the Indicated Investigator Assessment of Clinical Response in the mITT Population at the Post Therapy Evaluation (PTE) Visit |
303; 291; 12; 21; 45; 48 | — |
| SECONDARY Number of Participants With the Indicated Investigator Assessment of Clinical Response in the Clinically Evaluable-Post Therapy Evaluation (CE-PTE) Population |
278; 279; 6; 13 | — |
Eligibility Criteria
Inclusion Criteria
- Patients, ages 18 years or older who have signed the informed consent
- Has a qualifying skin and skin structure infection
- Female patients must not be pregnant at the time of enrollment
- Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug
Exclusion Criteria
- Infections where the outcome is strongly influenced by factors other than protocol-defined treatments and procedures, or that require antibacterial treatment for greater than 14 days
- Evidence of significant immunological disease
- Severe renal disease or requirement for dialysis
- Evidence of septic shock
- Has a history of hypersensitivity or allergic reaction to any tetracycline or to linezolid
- Has received an investigational drug within the past 30 days
- Women who are pregnant or nursing
Data sourced from ClinicalTrials.gov (NCT02877927) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.